Arthur Higgins (aged 52) has decided, at his own request, to leave Germany's Bayer Group during the first half of 2010 for personal reasons. Mr Higgins, a Scotsman who is currently president of the European Federation of Pharmaceutical Industry Associations, was appointed chairman of the Bayer HealthCare Executive Committee on July 1, 2004, and has been chief executive of Bayer HealthCare AG since January 1, 2006.
Meantime, Werner Wenning, Bayer AG CEO since 2002, is to extend his contract of service by eight months to September 30, 2010, a few weeks before his 64th birthday. In its meeting on Tuesday, Bayer's Supervisory Board appointed Netherlands-born Marijn Dekkers, currently president and CEO of US laboratory equipment manufacturer Thermo Fisher Scientific, to succeed Mr Wenning as CEO from October 1, 2010. Dr Dekkers will join the Bayer Management Board on January 1, 2010. In a transition phase he will also serve as CEO of Bayer HealthCare, succeeding Mr Higgins .
In other moves, following the Annual Stockholders' Meeting on April 30, 2010, the present chief financial officer, Klaus Kuhn, will take early retirement at the age of 58. The Supervisory Board has appointed Werner Baumann (46), currently a member of both the Board of Management and Executive Committee of Bayer HealthCare, to be Mr Kuhn's successor. Mr Baumann will also join the Bayer Management Board on January 1, 2010.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze